Mark Hilary Cunningham

This inventor holds 46 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 13 EPO patents, primarily in Anti-IL-23 Antibodies. Top assignees: Janssen Biotech, Inc., Centocor, Inc., Centocor Ortho Biotech Inc.. Active years: 2002-2024.

USPTO Granted Patents = 46 (Patent Applications = 6)

% Patents Active = 58.7

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 13 (Patent Applications = 7)

Average Co-Inventor Count = 5.7

ph-index = 14

Forward Citations = 847(Granted Patents)

Location History:

Waltham, MA (US) (2002)
Kenneth Square, PA (US) (2012)
Radnor, PA (US) (2011 - 2013)
Spring House, PA (US) (2015 - 2016)
Brooklyn, NY (US) (2004 - 2018)
Glenside, PA (US) (2020 - 2021)
Kennett Square, PA (US) (2002 - 2024)

Company Filing History:

25 out of 433

Janssen Biotech, Inc.

Centocor Ortho Biotech Inc.

Applied Research Systems Ars Holding N.v.

patents

6. 2 out of 217

Codman & Shurtleff, Inc.

9. 2 out of 834,411

Other

patents

Years Active: 2002-2024

Loading Chart...

Areas of Expertise:

Anti-IL-23 Antibodies

Toll-Like Receptor 3 Antagonists

Medical Devices

Inflammatory Conditions

Viral Infections

Implantable Pumps

Nucleic Acids

Compositions

Methods

Human Antibodies

Protein Delivery

46 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12161716 - Anti-IL-23 antibodies, compositions, methods and uses (2024-12-10),

2. 12129293 - Medical device for administering anti-IL-23 antibodies (2024-10-29),

3. 11185584 - Anti-IL-23 antibodies, compositions, methods and uses (2021-11-30),

4. 10954297 - Methods of treatment using human anti-IL-23 antibodies (2021-03-23),

5. 10576150 - Anti-IL-23 antibodies (2020-03-03),

6. 10272152 - Anti-IL-23 antibodies, compositions, methods and uses (2019-04-30),

7. 10128791 - Structures and methods for supporting solar panels (2018-11-13),

8. 10030070 - Human anti-IL-23 antibodies, compositions, methods and uses (2018-07-24),

9. 9932404 - Methods of reducing clinical symptoms of viral infection by administering a toll-like receptor 3 antagonist (2018-04-03),

10. 9807200 - System and method providing user interactivity across a network (2017-10-31),

11. 9783607 - Human anti-IL-23 antibodies, compositions, methods and uses (2017-10-10),

12. 9714287 - Anti-IL-23 antibody compositions (2017-07-25),

13. 9522957 - Method of treating an inflammatory condition by administering toll-like 3 receptor antagonists (2016-12-20),

14. 9505837 - Anti-IL-23 antibodies (2016-11-29),

15. 9481731 - Toll-like receptor 3 antagonists (2016-11-01),

Title: Mark Hilary Cunningham: A Pioneer in Anti-IL-23 Therapeutics

Introduction: Mark Hilary Cunningham, a seasoned inventor based in Brooklyn, NY, has made significant contributions to the field of biotechnology through his innovative work. With 46 patents to his name, Cunningham's inventions primarily focus on the development of anti-IL-23 antibodies, showcasing his dedication to advancing medical therapies.

Latest Patents: Among his most recent patents are groundbreaking inventions including "Anti-IL-23 antibodies, compositions, methods and uses" and "Medical device for administering anti-IL-23 antibodies." The first patent details an anti-IL-23 antibody featuring isolated nucleic acids that encode at least one anti-IL-23 antibody, alongside vectors and host cells. This invention has vital applications in diagnostic and therapeutic compositions. The second patent describes a human anti-IL-23p19 antibody, with similar applications in diagnostics and therapeutics, highlighting Cunningham's role in the development of crucial medical devices targeting IL-23 pathways.

Career Highlights: Throughout his esteemed career, Mark Cunningham has worked with reputable companies such as Janssen Biotech, Inc. and Centocor, Inc., where he has played a crucial role in advancing therapeutic technologies. His extensive experience and innovation in the field further demonstrate his commitment to enhancing patient care through scientific research.

Collaborations: Throughout his journey, Cunningham has collaborated with notable colleagues, including Raymond W Sweet and Jacqueline Benson. These partnerships have allowed for the exchange of ideas and strategies, enhancing the scope and impact of their collective innovations.

Conclusion: Mark Hilary Cunningham stands out as an influential inventor in the biotechnology landscape, particularly in the realm of anti-IL-23 therapies. With a robust portfolio of patents and a history of impactful collaborations, his contributions continue to shape the future of medical treatments and therapeutic advancements.